ClinicalTrials.gg
Not yet recruitingNCT07943013REGATTA-AFUpdated Nov 17, 2026

RF GP Ablation Added to PEF PVI for Paroxysmal AF

An interventional study of pulmonary vein isolation and roof line ablation and GP ablation in Atrial Fibrillation, sponsored by Institute for Clinical and Experimental Medicine. Not yet recruiting at 1 site in Czechia. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Institute for Clinical and Experimental Medicine · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 184 studies in Atrial Fibrillation with a site in Czechia — 39 open to participants now, 50 under way, 6 of them phase 3. Atrial Fibrillation · Czechia.

Planned enrollment
65th of 153
250 · median 200
Started
2027
with 1 other
No phase
96 of 184
23 open now
Primary completion
2028-04
later than 39 of 49 live
Registered
175th of 184
by date

Among the 184 studies in Atrial Fibrillation with a site in Czechia, this one is the 65th largest by planned enrollment of the 153 interventional ones that give a count, is one of 2 that started in 2027, is one of 96 with no phase, reaches primary completion later than 39 of the 49 other live ones, and was the 175th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

39 of the 184 studies in Atrial Fibrillation with a site in Czechia are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Atrial Fibrillation with a site in Czechia, or all of them as a file.
02

Study summary

This study will investigate whether adjunctive RF GP ablation, when added to PF PVI, improves freedom from AF or atrial tachycardia (AT). By directly addressing the potential limitation of autonomic modulation associated with PF ablation alone, this study will provide mechanistic and clinically relevant insights into the role of parasympathetic modulation of the heart in preventing AF recurrence.

The results are expected to yield novel, clinically meaningful evidence that may help refine and optimize catheter ablation workflows, particularly in the era of non-thermal energy sources.

Read the detailed description

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and pulmonary vein isolation (PVI) represents the cornerstone therapeutic strategy in patients with symptomatic paroxysmal AF. Pulsed electric field (PEF) ablation is a novel energy source that enables safe and durable PVI but has a limited and only transient effect on the autonomic nervous system, which plays an important role in the pathogenesis of AF. Previous studies have shown that modification of ganglionated plexi (GP) using radiofrequency (RF) energy may result in more effective and sustained parasympathetic atrial denervation, thereby potentially improving long-term ablation outcomes.

The aim of this project is to compare the efficacy of PEF PVI alone versus a combined strategy of PEF PVI plus adjunctive RF GP ablation in patients with antiarrhythmic drug-refractory paroxysmal AF. This is a multicentre, randomized, single-blind superiority trial. A total of 250 patients will be enrolled across three highly specialized centres in the Czech Republic. The primary endpoint is freedom from recurrent AF/atrial tachycardia lasting >30 seconds during 12 months of follow-up (excluding a 2-month blanking period) without the use of Class I/III antiarrhythmic drugs. Secondary endpoints include arrhythmia burden assessed by long-term ECG monitoring, quality of life, procedural safety, and detailed evaluation of cardiac autonomic function using both invasive and non-invasive methods.

The project will provide the first direct clinical evidence on the benefit of targeted autonomic modulation added to PEF PVI. The results may substantially influence the optimization of ablation strategies in paroxysmal AF and contribute to the refinement of future clinical guidelines.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • atrial fibrillation
  • catheter ablation
  • ganglionated plexi
  • radiofrequency energy
  • pulsed electric field energy
  • autonomic nervous system
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with drug-resistant symptomatic paroxysmal AF meeting all the following criteria:

    1. Paroxysmal AF that terminates spontaneously or with intervention within 7 days of onset.
    2. Failed AAD treatment, defined as ineffective, intolerant or inappropriate ≥1 Class I-IV AAD.
  2. Patients who are ≥30 and ≤65 years of age on the day of enrolment.
  3. Patients who are willing and capable of:

    1. Providing to undergo study procedures AND
    2. Participating in all examinations, follow-up visits, and tests associated with this clinical study.
  4. Effective for women of .
  5. Effective oral anticoagulation for >3 weeks before the planned ablation procedure.

Exclusion criteria

Exclusion Criteria:

  1. Persistent, long-standing persistent, or permanent AF.
  2. AF secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
  3. Left atrial (LA) anteroposterior diameter ≥50 mm (by transthoracic echocardiography).
  4. \<40%.
  5. Autonomic dysfunction, e.g., cardiac autonomic neuropathy due to diabetes mellitus.
  6. Any prior atrial endocardial or epicardial ablation procedure, including cavotricuspid isthmus (CTI) ablation or right-sided AT.
  7. Any prior atrial surgery.
  8. Intra-atrial septal patch or interatrial shunt.
  9. General of catheter ablation
  10. LA appendage closure, device, or occlusion, past or anticipated.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    RF GP + PEF PVI

    Radiofrequency ablation of ganglionated plexi added to pulmonary vein isolation and roof line ablation using pulsed electric field

    Procedure: pulmonary vein isolation and roof line ablation · Procedure: GP ablation

  • Active comparator
    PEF PVI

    Pulmonary vein isolation and roof line ablation using pulsed electric field energy

    Procedure: pulmonary vein isolation and roof line ablation

Interventions

  • Procedurepulmonary vein isolation and roof line ablation

    isolation of pulmonary veins and roof line ablation using pulsed electric energy

  • ProcedureGP ablation

    ablation of GP using radiofrequency energy

06

What researchers measure

Primary outcomes

  1. Freedom from recurrent AF/AT >30 s during the first 12 months

    The primary outcome of the study is freedom from recurrent AF/AT \>30 s during the first 12 months (excluding a 2-month blanking period) after the procedure without the use of Class I or III AADs.

    Time frame: From the ablation procedure through the 12-month follow-up.

Secondary outcomes

  1. Quality of life

    This measure will be assessed by the AFEQT questionnaire. A higher score = a better quality of life (0 = worst possible quality of life, 50 = intermediate impairment, and 100 = best possible quality of life).

    Time frame: Baseline and at the 12-month visit.

  2. Periprocedural complications, MACE

    periprocedural complications, including cardiac tamponade, stroke/TIA, major bleeding requiring intervention or transfusion, vascular access complications requiring treatment; major adverse cardiac events during follow-up

    Time frame: From the ablation procedure through the 12-month follow-up.

  3. Acute vagal denervation assessed by ECVS

    ECVS will be performed during the ablation procedure at baseline and 20 minutes after the last PF of RF application. The longest P-P and R-R pauses ( in seconds) during ECVS will be recorded.

    Time frame: Periprocedural

  4. Long-term cardiac vagal denervation

    Patients will undergo atropine testing consisting of an intravenous bolus of atropine sulfate. ECG will be recorded immediately before and 5 minutes after the injection.

    Time frame: Baseline and at the 12-month visit.

  5. Vagal atrial induction test (VAFIT)

    This test will be performed to assess the inducibility of AF/AF at baseline and at the end of the procedure. The induction protocol will use programmed atrial stimulation (a short train of 4 cycles at 120 bpm followed by one extrastimulus) from the low lateral right atrium, synchronised with the ECVS.

    Time frame: Periprocedural

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Apr 2028, 12 months later.

Of 794 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 12 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Nov 17, 2026
StartEst.
Apr 1, 2027
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943013
Lead sponsor
Institute for Clinical and Experimental Medicine
Collaborators
Faculty Hospital Kralovske Vinohrady, University Hospital Olomouc
Responsible party
Predrag Stojadinovic (MD, PHD, Institute for Clinical and Experimental Medicine) — Principal investigator
First posted
Nov 17, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion